<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144416</url>
  </required_header>
  <id_info>
    <org_study_id>P06029</org_study_id>
    <nct_id>NCT01144416</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)</brief_title>
  <acronym>PURSUE</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Active-controlled, Non-inferiority Trial to Investigate the Efficacy and Safety of a Single Injection of SCH 900962 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women Aged 35 to 42 Years (Phase 3; Protocol No. P06029)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that a single injection of SCH 900962/MK-8962 is
      non-inferior to daily injections of recombinant follicle-stimulating hormone (recFSH) during
      the first week of ovarian stimulation in terms of the number of vital pregnancies (ie,
      presence of at least one fetus with heart activity as assessed by ultrasound at least 35 days
      after embryo transfer) in women aged 35 to 42 years undergoing controlled ovarian stimulation
      (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Vital Pregnancy</measure>
    <time_frame>Vital pregnancy will be assessed by ultrasound at least 35 days after embryo transfer (with a timeframe of 35-42 days). Time from start of study treatment to embryo transfer is maximally 24 days.</time_frame>
    <description>Vital pregnancy was defined as the presence of at least 1 fetus with heart activity at least 35 days (≥5 weeks) after embryo transfer in the controlled ovarian stimulation (COS) treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Oocytes Retrieved Per Attempt</measure>
    <time_frame>Maximally 21 days after the start of study treatment.</time_frame>
    <description>The number of cumulus oocyte-complexes retrieved was summarized per treatment group and per attempt (= per started COS cycle).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>Approximately nine months after embryo transfer</time_frame>
    <description>The live-birth rate is the percentage of participants with at least 1 live born infant after an ongoing pregnancy in the controlled ovarian stimulation (COS)treatment cycle relative to the number of participants treated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS)</measure>
    <time_frame>Up to approximately 1 month after oocyte pick-up</time_frame>
    <description>Grade II (moderate OHSS) is characterized by distinct ovarian cysts (ovary size 8-10 cm), accompanied by abdominal pain and tension, nausea, vomiting, diarrhea.
Grade III (severe OHSS) is characterized by enlarged cystic ovaries (ovary size &gt;10 cm), accompanied by ascites and occasionally hydrothorax. Abdominal tension and pain may be severe. Pronounced hydrothorax together with an abdominal cavity filled with cysts and fluid elevating the diaphragm, may cause severe breathing difficulties. Large quantities of fluid inside the cysts and in the peritoneal and pleural cavities cause hemoconcentration and increased blood viscosity. In rare cases, the syndrome may further be complicated by the occurrence of thromboembolic phenomena.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event</measure>
    <time_frame>Up to time of embryo transfer (maximum of 24 days after start of study drug)</time_frame>
    <description>The number of participants who started stimulation but did not undergo embryo transfer due to (S)AEs will be compared between the treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1424</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Single injection of 150 µg SCH 900962 (MK-8962)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily 300 IU recFSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SCH 900962 / Corifollitropin alfa / Org 36286</intervention_name>
    <description>SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.</description>
    <arm_group_label>Single injection of 150 µg SCH 900962 (MK-8962)</arm_group_label>
    <other_name>MK-8962</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RecFSH / follitropin beta</intervention_name>
    <description>RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.</description>
    <arm_group_label>Daily 300 IU recFSH</arm_group_label>
    <other_name>Follistim® AQ Cartridge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for SCH 900962</intervention_name>
    <description>Supplied as a pre-filled syringe containing an identical solution when
compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.</description>
    <arm_group_label>Daily 300 IU recFSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for recFSH</intervention_name>
    <description>Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.</description>
    <arm_group_label>Single injection of 150 µg SCH 900962 (MK-8962)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent for trial P06029 as well as for
             the Frozen-Thawed Embryo Transfer (FTET) follow-up trial P06031, and for the
             pharmacogenetic analysis (if applicable).

          -  Female and &gt;=35 to &lt;=42 years of age with indication for COS and IVF/ICSI.

          -  Body weight ≥50.0 kg, body mass index (BMI) &gt;=18.0 to &lt;=32.0 kg/m2.

          -  Regular spontaneous menstrual cycle with variation not outside the 24-35 days.

          -  Ejaculatory sperm must be available (donated and/or cryopreserved sperm is allowed).

          -  Results of clinical laboratory tests, cervical smear, physical examination within
             normal limits or clinically acceptable to the investigator.

          -  Adhere to trial schedule.

        Exclusion Criteria:

          -  A recent history of/or any current endocrine abnormality.

          -  A history of ovarian hyper-response or ovarian hyperstimulation syndrome (OHSS).

          -  A history of/or current polycystic ovary syndrome.

          -  More than 20 basal antral follicles &lt;11 mm (both ovaries combined) in the early
             follicular phase.

          -  Less than 2 ovaries or any other ovarian abnormality.

          -  Unilateral or bilateral hydrosalpinx.

          -  Intrauterine fibroids ≥5 cm or any clinically relevant pathology, which could impair
             embryo implantation or pregnancy continuation.

          -  More than three unsuccessful COS cycles for IVF/ICSI since the last established
             ongoing pregnancy (if applicable).

          -  A history of non- or low ovarian response to FSH/human menopausal gonadotropin (hMG)
             treatment.

          -  A history of recurrent miscarriage.

          -  FSH &gt;15.0 IU/L or luteinizing hormone (LH) &gt;12.0 IU/L during the early follicular
             phase.

          -  Positive for human immunodeficiency virus (HIV) or Hepatitis B.

          -  Contraindications for the use of gonadotropins or gonadotropin releasing hormone
             (GnRH) antagonists.

          -  A recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular,
             gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring
             regular treatment.

          -  Smoking or recently stopped smoking (ie, within the last 3 months prior to signing
             informed consent).

          -  A recent history or presence of alcohol or drug abuse.

          -  The participant or the sperm donor has known gene defects, genetic abnormalities, or
             abnormal karyotyping, relevant for the current indication or for the health of the
             offspring.

          -  Prior or concomitant medications disallowed by protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, Elbers J, Gordon K, Mannaerts B; Pursue investigators. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril. 2015 Jul;104(1):94-103.e1. doi: 10.1016/j.fertnstert.2015.04.018. Epub 2015 May 21.</citation>
    <PMID>26003273</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <results_first_submitted>November 27, 2012</results_first_submitted>
  <results_first_submitted_qc>November 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 27, 2012</results_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <keyword>Follicle Stimulating Hormone, Human</keyword>
  <keyword>Fertilization In Vitro</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women, aged between 35 and 42 years, with an indication for controlled ovarian stimulation and in vitro fertilization/intracytoplasmic sperm injection without a history of previous hyper or low ovarian response to follicle-stimulating hormone/human menopausal gonadotropins, ovarian hyperstimulation syndrome (OHSS), or polycystic ovary syndrome.</recruitment_details>
      <pre_assignment_details>1424 participants were originally enrolled in the study. All data for 1 participant, who was incorrectly randomized and did not receive study medication and for all 33 participants at 1 clinical site were excluded from all analyses, including disposition, prior to unblinding. Only women who became pregnant continued into Pregnancy Follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
          <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recombinant follicle-stimulating hormone (recFSH) from Stimulation Days 1-7</description>
        </group>
        <group group_id="P2">
          <title>Daily 300 IU recFSH</title>
          <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="694"/>
                <participants group_id="P2" count="696"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="632"/>
                <participants group_id="P2" count="647"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient ovarian response</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Risk of OHSS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Too high ovarian response</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No/too few/bad oocytes</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No or abnormal fertilization</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No/too few/bad quality embryos</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pregnancy Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154">Participants received 150 ug SCH 900962 in Intervention Period and became pregnant.</participants>
                <participants group_id="P2" count="167">Participants received daily injections of 300 IU recFSH in Intervention Period and became pregnant.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
          <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
        </group>
        <group group_id="B2">
          <title>Daily 300 IU recFSH</title>
          <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="694"/>
            <count group_id="B2" value="696"/>
            <count group_id="B3" value="1390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="2.2"/>
                    <measurement group_id="B2" value="38.0" spread="2.2"/>
                    <measurement group_id="B3" value="38.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="694"/>
                    <measurement group_id="B2" value="696"/>
                    <measurement group_id="B3" value="1390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vital Pregnancy</title>
        <description>Vital pregnancy was defined as the presence of at least 1 fetus with heart activity at least 35 days (≥5 weeks) after embryo transfer in the controlled ovarian stimulation (COS) treatment cycle</description>
        <time_frame>Vital pregnancy will be assessed by ultrasound at least 35 days after embryo transfer (with a timeframe of 35-42 days). Time from start of study treatment to embryo transfer is maximally 24 days.</time_frame>
        <population>Intent-To-Treat Group: all randomized participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to. Participants who did not have embryo transfer or who were lost to follow-up before the ultrasound assessment to confirm vital pregnancy were counted as non-pregnant.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
            <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
          </group>
          <group group_id="O2">
            <title>Daily 300 IU recFSH</title>
            <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vital Pregnancy</title>
          <description>Vital pregnancy was defined as the presence of at least 1 fetus with heart activity at least 35 days (≥5 weeks) after embryo transfer in the controlled ovarian stimulation (COS) treatment cycle</description>
          <population>Intent-To-Treat Group: all randomized participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to. Participants who did not have embryo transfer or who were lost to follow-up before the ultrasound assessment to confirm vital pregnancy were counted as non-pregnant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pre-defined non-inferiority margin was -8%</non_inferiority_desc>
            <param_type>Difference in percentage vital pregnancy</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Oocytes Retrieved Per Attempt</title>
        <description>The number of cumulus oocyte-complexes retrieved was summarized per treatment group and per attempt (= per started COS cycle).</description>
        <time_frame>Maximally 21 days after the start of study treatment.</time_frame>
        <population>Intent-To-Treat (ITT) Group, defined as all randomized participants who received one or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to. The number of oocytes retrieved were set to zero for participants who did not have oocyte retrieval.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
            <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
          </group>
          <group group_id="O2">
            <title>Daily 300 IU recFSH</title>
            <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved Per Attempt</title>
          <description>The number of cumulus oocyte-complexes retrieved was summarized per treatment group and per attempt (= per started COS cycle).</description>
          <population>Intent-To-Treat (ITT) Group, defined as all randomized participants who received one or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to. The number of oocytes retrieved were set to zero for participants who did not have oocyte retrieval.</population>
          <units>Number of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="7.2"/>
                    <measurement group_id="O2" value="10.3" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pre-defined non-inferiority margin was -3 oocytes.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rate</title>
        <description>The live-birth rate is the percentage of participants with at least 1 live born infant after an ongoing pregnancy in the controlled ovarian stimulation (COS)treatment cycle relative to the number of participants treated.</description>
        <time_frame>Approximately nine months after embryo transfer</time_frame>
        <population>Intent-To-Treat Group: all randomized participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
            <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recombinant follicle-stimulating hormone (recFSH) from Stimulation Days 1-7</description>
          </group>
          <group group_id="O2">
            <title>Daily 300 IU recFSH</title>
            <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <description>The live-birth rate is the percentage of participants with at least 1 live born infant after an ongoing pregnancy in the controlled ovarian stimulation (COS)treatment cycle relative to the number of participants treated.</description>
          <population>Intent-To-Treat Group: all randomized participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the treatment they were randomized to.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="694"/>
                <count group_id="O2" value="696"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The pre-defined non-inferiority margin was -8%</non_inferiority_desc>
            <param_type>Difference in Live Birth Rates</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS)</title>
        <description>Grade II (moderate OHSS) is characterized by distinct ovarian cysts (ovary size 8-10 cm), accompanied by abdominal pain and tension, nausea, vomiting, diarrhea.
Grade III (severe OHSS) is characterized by enlarged cystic ovaries (ovary size &gt;10 cm), accompanied by ascites and occasionally hydrothorax. Abdominal tension and pain may be severe. Pronounced hydrothorax together with an abdominal cavity filled with cysts and fluid elevating the diaphragm, may cause severe breathing difficulties. Large quantities of fluid inside the cysts and in the peritoneal and pleural cavities cause hemoconcentration and increased blood viscosity. In rare cases, the syndrome may further be complicated by the occurrence of thromboembolic phenomena.</description>
        <time_frame>Up to approximately 1 month after oocyte pick-up</time_frame>
        <population>All-Subjects-Treated (AST) Group, defined as all participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the active treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
            <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
          </group>
          <group group_id="O2">
            <title>Daily 300 IU recFSH</title>
            <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate or Severe Ovarian Hyperstimulation Syndrome (OHSS)</title>
          <description>Grade II (moderate OHSS) is characterized by distinct ovarian cysts (ovary size 8-10 cm), accompanied by abdominal pain and tension, nausea, vomiting, diarrhea.
Grade III (severe OHSS) is characterized by enlarged cystic ovaries (ovary size &gt;10 cm), accompanied by ascites and occasionally hydrothorax. Abdominal tension and pain may be severe. Pronounced hydrothorax together with an abdominal cavity filled with cysts and fluid elevating the diaphragm, may cause severe breathing difficulties. Large quantities of fluid inside the cysts and in the peritoneal and pleural cavities cause hemoconcentration and increased blood viscosity. In rare cases, the syndrome may further be complicated by the occurrence of thromboembolic phenomena.</description>
          <population>All-Subjects-Treated (AST) Group, defined as all participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the active treatment they actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="692"/>
                <count group_id="O2" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event</title>
        <description>The number of participants who started stimulation but did not undergo embryo transfer due to (S)AEs will be compared between the treatment groups.</description>
        <time_frame>Up to time of embryo transfer (maximum of 24 days after start of study drug)</time_frame>
        <population>All-Subjects-Treated (AST) Group, defined as all participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the active treatment they actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
            <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
          </group>
          <group group_id="O2">
            <title>Daily 300 IU recFSH</title>
            <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of 300 IU recFSH from Stimulation Days 1-7</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Cancelled the Cycle Due to a (Serious) Adverse Event</title>
          <description>The number of participants who started stimulation but did not undergo embryo transfer due to (S)AEs will be compared between the treatment groups.</description>
          <population>All-Subjects-Treated (AST) Group, defined as all participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the active treatment they actually received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="692"/>
                <count group_id="O2" value="698"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were reported for both pretreatment and active treatment periods of the Intervention Phase of the study, inclusive. AEs for the Follow-up Period include events reported by the mother/fetus/infant (up to 4-12 weeks after birth).</time_frame>
      <desc>Safety Population: All Subjects Treated, defined as all participants who received 1 or more dose(s) of SCH 900962 or recFSH. Participants were grouped according to the active treatment they actually received. Three participants randomized to SCH900962 were treated with recFSH, and 1 participant randomized to recFSH was treated with SCH900962.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Injection of 150 µg SCH 900962/MK-8962</title>
          <description>Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7</description>
        </group>
        <group group_id="E2">
          <title>Daily 300 IU recFSH</title>
          <description>Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7</description>
        </group>
        <group group_id="E3">
          <title>Single Injection of 150 µg SCH 900962/MK-8962-Follow-up</title>
          <description>Participants who received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7 during Intervention Period and became pregnant.</description>
        </group>
        <group group_id="E4">
          <title>Daily 300 IU recFSH -Follow-up</title>
          <description>Participants who received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7 during Intervention Period and became pregnant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="692"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="698"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="112" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL HEART RATE DECELERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VENTRICULAR HYPERTROPHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ACCESSORY AURICLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ANKYLOGLOSSIA CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ARNOLD-CHIARI MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BRAIN MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CHORDEE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL AORTIC ANOMALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL CARDIOVASCULAR ANOMALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL CENTRAL NERVOUS SYSTEM ANOMALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL CHOROID PLEXUS CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL CYSTIC DISEASE OF LIVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL GENITAL MALFORMATION MALE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL MELANOCYTIC NAEVUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL ORAL MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL PIGMENTATION DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL PYELOCALIECTASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONGENITAL TORTICOLLIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DACRYOSTENOSIS CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DEAFNESS CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DERMOID CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSMORPHISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>EXOMPHALOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FALLOT'S TETRALOGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL CYSTIC HYGROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HAEMANGIOMA CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HIGH ARCHED PALATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HIP DYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HOODED PREPUCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYDROCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPOPLASTIC LEFT HEART SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPOSPADIAS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INTESTINAL MALROTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>LARYNGOMALACIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PATENT DUCTUS ARTERIOSUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PECTUS EXCAVATUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PHIMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PLAGIOCEPHALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERY STENOSIS CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SEPTUM PELLUCIDUM AGENESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SKULL MALFORMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SPINA BIFIDA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TALIPES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TELANGIECTASIA CONGENITAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRISOMY 13</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRISOMY 18</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRISOMY 21</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRISOMY 22</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>URACHAL ABNORMALITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VENTRICULAR SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>FUNCTIONAL GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>TEMPERATURE REGULATION DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABORTION INFECTED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CHORIOAMNIONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ENDOMETRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SEPSIS NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL HEART RATE ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL HEART RATE DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL NON-STRESS TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FEEDING DISORDER NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RETROGNATHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HEMIANOPIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CEREBRAL VENTRICLE DILATATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MIGRAINE WITH AURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="692"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ARRESTED LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="154"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BREECH PRESENTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CEPHALO-PELVIC DISPROPORTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CERVICAL INCOMPETENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DISCORDANT TWIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FAILED INDUCTION OF LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL GROWTH RESTRICTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL MACROSOMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FOETAL MALPRESENTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GESTATIONAL DIABETES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GESTATIONAL HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE IN PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HELLP SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>JAUNDICE NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>LOW BIRTH WEIGHT BABY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MECONIUM IN AMNIOTIC FLUID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MULTIPLE PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>OLIGOHYDRAMNIOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIPARTUM CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PLACENTA PRAEVIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PLACENTA PRAEVIA HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>POSTPARTUM HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PRE-ECLAMPSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREGNANCY WITH ADVANCED MATERNAL AGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREMATURE BABY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="25" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E4" events="28" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREMATURE LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREMATURE RUPTURE OF MEMBRANES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREMATURE SEPARATION OF PLACENTA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREVIOUS CAESAREAN SECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PROLONGED LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PROLONGED PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RETAINED PLACENTA OR MEMBRANES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SMALL FOR DATES BABY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>STILLBIRTH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>THREATENED LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRANSVERSE PRESENTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TWIN PREGNANCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UMBILICAL CORD AROUND NECK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UTERINE CERVICAL LACERATION DURING LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VASA PRAEVIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASE NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN HYPERSTIMULATION SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CERVIX DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CERVIX OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PELVIC PROLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SHORTENED CERVIX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ATELECTASIS NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY DYSPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>IMMATURE RESPIRATORY SYSTEM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INFANTILE APNOEIC ATTACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEONATAL ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEONATAL RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEONATAL RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TRANSIENT TACHYPNOEA OF THE NEWBORN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CAESAREAN SECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MYOMECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SELECTIVE ABORTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="267" subjects_at_risk="692"/>
                <counts group_id="E2" subjects_affected="262" subjects_at_risk="698"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="154"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="154"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="50" subjects_affected="47" subjects_at_risk="692"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="698"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E4" events="15" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="692"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="698"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="154"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="692"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="698"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" events="17" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="692"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="698"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="692"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="698"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="154"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="692"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="698"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="64" subjects_affected="61" subjects_at_risk="692"/>
                <counts group_id="E2" events="72" subjects_affected="69" subjects_at_risk="698"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="101" subjects_affected="98" subjects_at_risk="692"/>
                <counts group_id="E2" events="86" subjects_affected="83" subjects_at_risk="698"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="154"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERINEAL LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="98" subjects_affected="73" subjects_at_risk="692"/>
                <counts group_id="E2" events="101" subjects_affected="73" subjects_at_risk="698"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION MISSED</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="692"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="698"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>AFTERBIRTH PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>GESTATIONAL DIABETES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="154"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>JAUNDICE NEONATAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="33" subjects_affected="31" subjects_at_risk="154"/>
                <counts group_id="E4" events="30" subjects_affected="27" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PREMATURE BABY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="154"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VOMITING IN PREGNANCY</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="692"/>
                <counts group_id="E2" events="35" subjects_affected="31" subjects_at_risk="698"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="154"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>PELVIC DISCOMFORT</sub_title>
                <counts group_id="E1" events="57" subjects_affected="52" subjects_at_risk="692"/>
                <counts group_id="E2" events="66" subjects_affected="57" subjects_at_risk="698"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="692"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="698"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEONATAL RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="692"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="698"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agreed not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report(s) any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

